PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYM...

por Barrientos, J. C., Barr, P. M., Mato, A. R., Tam, C. S., Ghia, P., Moreno, C., Kay, N. E., Siddiqi, T., Szafer-Glusman, E., Zhou, C., Neumayr, L., Krigsfeld, G., Wierda, W. G., Shanafelt, T.
Publicado 2022

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

por Montillo, M, O'Brien, S, Tedeschi, A, Byrd, J C, Dearden, C, Gill, D, Brown, J R, Barrientos, J C, Mulligan, S P, Furman, R R, Cymbalista, F, Plascencia, C, Chang, S, Hsu, E, James, D F, Hillmen, P
Publicado 2017

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

por Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C
Publicado 2018